Protein-energy malnutrition (PEM) affects ∼16% of patients at admission for stroke. We previously modeled this in a gerbil global cerebral ischemia model and found that PEM impairs functional outcome and influences mechanisms of ischemic brain injury and recovery. Since this model is no longer reliable, we investigated the utility of the rat 2-vessel occlusion (2-VO) with hypotension model of global ischemia for further study of this clinical problem. Male, Sprague-Dawley rats were exposed to either control diet (18% protein) or PEM induced by feeding a low protein diet (2% protein) for 7d prior to either global ischemia or sham surgery. PEM did not significantly alter the hippocampal CA1 neuron death (p = 0.195 by 2-factor ANOVA) or the increase in dendritic injury caused by exposure to global ischemia. Unexpectedly, however, a strong trend was evident for PEM to decrease the consistency of hippocampal damage, as shown by an increased incidence of unilateral or no hippocampal damage (p = 0.069 by chi-square analysis). Although PEM caused significant changes to baseline arterial blood pH, pO2, pCO2, and fasting glucose (p < 0.05), none of these variables (nor hematocrit) correlated significantly with CA1 cell counts in the malnourished group exposed to 2-VO (p ≥ 0.269). Intra-ischemic tympanic temperature and blood pressure were strictly and equally controlled between ischemic groups. We conclude that co-existing PEM confounded the consistency of hippocampal injury in the 2-VO model. Although the mechanisms responsible were not identified, this model of brain ischemia should not be used for studying this co-morbidity factor.
Keywords: 2-vessel occlusion, global ischemia, protein-energy malnutrition, ischemic brain injury, rat, experimental stroke model, low protein, dendritic, ischemia, pCO2, hematocrit, Intra-ischemic, tympanic, hippocampal, PEM, 2-VO
Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Current Drug Targets Regulation of Neuronal Cell Death and Neurodegeneration by Members of the Bcl-2 Family: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders Triggers of Cell Death in the Developing Brain
Current Pediatric Reviews CT and MR Imaging of the Encephalopathic Child
Current Medical Imaging Inflammation and Inflammatory Cell Recruitment in Acute Cerebrovascular Diseases
Current Immunology Reviews Progress in COX-2 Inhibitors: A Journey So Far
Current Medicinal Chemistry The Updated Role of Oxidative Stress in Subarachnoid Hemorrhage
Current Drug Delivery Cerebral White Matter Injuries Following a Hypoxic/Ischemic Insult During the Perinatal Period: Pathophysiology, Prognostic Factors, and Future Strategy of Treatment Approach. A Minireview
Current Pharmaceutical Design Timing is Everything
Current Neurovascular Research TrkB Receptor Agonist 7, 8 Dihydroxyflavone Triggers Profound Gender- Dependent Neuroprotection in Mice After Perinatal Hypoxia and Ischemia
CNS & Neurological Disorders - Drug Targets Cycle Helmets for Children- Education or Enforcement?
Current Pediatric Reviews Minor Head Trauma in the Pediatric Emergency Department: Decision Making Nodes
Current Pediatric Reviews Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca<sup>2+</sup> Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
CNS & Neurological Disorders - Drug Targets Cyclooxygenase Inhibition in Ischemic Brain Injury
Current Pharmaceutical Design Spreading Depolarization Waves in Neurological Diseases: A Short Review about its Pathophysiology and Clinical Relevance
Current Neuropharmacology Neuroprotection in Hypoxic-Ischemic Brain Injury Targeting Glial Cells
Current Pharmaceutical Design Future Perspectives on the Fibrinolytic Therapy of Intracerebral Hemorrhages
Central Nervous System Agents in Medicinal Chemistry Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Moderate Hypothermia and Fever
Current Pharmaceutical Design